Manage your expectations about Kyprolis approval
This weekend, I heard from a number of patients that were excited about the sudden availability of carfilzomib (trade name Kyprolis) as soon as next month. Several wanted to drop their ongoing...
View ArticleOnyx’s Multiple Myeloma Drug Kyprolis Gets FDA Approval, Now What?
FDA approval of multiple myeloma drug Kyprolis has driven up Onyx Pharma’s shares by 11.7%. The drug Kyprolis (carfilzomib) has been approved for multiple myeloma patients who have undergone a minimum...
View ArticleIMF Support Group Leaders’ Summit – Dallas, Texas (Part One)
The IMF staff tries to do so much on these annual group leader weekends. Medical information, ways to help facilitate groups more effectively, sharing and caring exercises. It’s exciting, but a lot to...
View ArticleOnyx Pharma KYPROLIS: Safety Concerns And Prescribing Information
Accelerated approval of Kyprolis/Carfilzomib is big news for Onyx. Onyx Pharma’s homepage has Kyprolis smeared all over and if you need information on prescribing details of carfilzomib, you can...
View ArticleAn inside look at the creation of Onyx 360
Every large pharmaceutical company has some sort of patient support program. Most help low income patients gain access to their drugs, usually by providing free or discounted product. Last December at...
View ArticleBREAKING NEWS: Dr. Berenson’s Kyprolis results live up to the hype!
Two weeks ago, Dr. Berenson hinted on our Myeloma Cure Panel broadcast that there were surprisingly hopeful numbers in a study he was conducting on relapsed/refractory patients. This trial is one of...
View ArticleKyprolis proving to be a surprisingly effective combination drug
Yesterday am I promised another post later in the day. Sorry, but after I got home I fell asleep on the couch! As promised, here are more of my notes and thoughts about myeloma related research from...
View ArticleImpatient readers? I LOVE IT!
I love the fact that my email in-box is filling-up with notes from readers who are interested in specific poster and oral presentations from this year’s ASH! Many of those interested are either in a...
View ArticleNew combo therapy study results from ASH
If you missed it, go back and read Sunday’s post about the almost miraculous new leukemia therapy, developed by researchers at the University of Pennsylvania. Forget “Dreaming of a white Christmas.”...
View ArticleBREAKING NEWS: HIV drug may help Velcade and Kyprolis work better
I haven’t had a chance to review the data yet, but Danny Parker forwarded me these links moments ago: Pat, This just off the medical press and called out by Dr. Robert Orlowski. Oral protease...
View ArticleResponding to IMiD and proteasome inhibitor may be game changer
Friday I left everyone hanging when I wrote: Monday I am going to explain how this seemingly mundane result–a 0.2 M-spike–may have been the most fateful news I have ever received as a soon to be six...
View ArticleHigh risk myeloma patients: Would you like the good or bad news first?
Depending on which myeloma expert you ask, roughly 85% of multiple myeloma patients are considered to be “standard” or “low risk.” I’m fortunate to fall into this most common category. And because I...
View ArticleBREAKING NEWS: Amgen to buy Onyx Pharmaceuticals
This is BIG NEWS, especially for a Sunday afternoon: Amgen to Acquire Onyx Pharmaceuticals for $125 per Share in Cash Attractive Addition to Amgen’s Leading Oncology Portfolio and Pipeline Kyprolis(R)...
View ArticleReminder: On-air myeloma support group meeting tomorrow at 6 PM
I would like to remind my readers about tomorrow evening’s on-air myeloma support group, sponsored by Cure Talk. Priya Menon produces the broadcasts. She blogged about how the concept got started–and...
View ArticleOn Pomalyst and Carfilzomib (Kyprolis) Now, Paula van Riper Shares Her 14...
We had a wonderful guest with us on our Live On-Air Myeloma Support Group Meeting broadcast on 30 September 2013 @ 6pm ET- Paula Van Riper. Paula is a 14 year myeloma survivor and has been treated with...
View ArticlePatient Snapshot update: Chuck from Georgia
Back in September I featured Chuck from Georgia in a series of Patient Snapshot posts. Chuck has been battling a very aggressive form of multiple myeloma. We are so fortunate that he has allowed us...
View ArticleNotable Kyprolis data from ASH
2013 was a big year for Onyx Pharmaceutical and their novel therapy agent, Kyprolis (carfilzomib). First, the FDA approved Kyprolis for use in relapsed/refractory multiple myeloma patients in July....
View ArticleBREAKING NEWS: For many, more Kyprolis is better
A Stage 2 clinical trial has confirmed what many myeloma specialists already knew: increasing Kyprolis dosing improves patient outcomes. Here are the results, published in BLOOD and run in Hem Onc...
View ArticleKyprolis isn’t perfect, but I’ll take it (someday)
As promised, here’s more about the new Kyprolis (carfilzomib) ASPIRE study I introduced you to yesterday. I’m a patient that’s slowly running out of therapy options. From that standpoint I will be...
View ArticleRelapsed/refractory patients face difficult choices
I reported back Wednesday afternoon after meeting with my myeloma specialist, Dr. Roy, at Mayo Clinic. The contrast between Dr. Roy’s slow and steady incremental therapy approach, and the “hit the...
View Article
